In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2

New antiretroviral drugs are needed to treat HIV-2 infected patients failing therapy. Herein, we evaluate the activity of novel reverse transcriptase inhibitors tenofovir alafenamide (TAF) and OBP-601(2,3-didehydro-3-deoxy-4-ethynylthymidine) against primary isolates from HIV-2 infected patients exp...

ver descrição completa

Detalhes bibliográficos
Autor principal: Bártolo, I (author)
Outros Autores: Borrego, P (author), Gomes, P (author), Gonçalves, F (author), Caixas, U (author), Pinto, IV (author), Taveira, N (author)
Formato: article
Idioma:eng
Publicado em: 2020
Assuntos:
Adenine
Anti-HIV Agents
Drug Discovery
HIV-2
Humans
Microbial Sensitivity Tests
Mutation
Reverse Transcriptase Inhibitors
Virus Replication
Drug Resistance, Multiple, Viral
HSJ MED
Texto completo:http://hdl.handle.net/10400.17/3444
País:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3444

Texto Completo

http://hdl.handle.net/10400.17/3444

Registos relacionados